ASX:MSBMesoblast Stock Price, Forecast & News

A$3.39

+0.15 (+4.63 %)

(As of 05/13/2020)

Add

Compare

Today's Range

A$3.23

Now: A$3.39▼

A$3.42

50-Day Range

A$1.35

MA: A$2.78▼

A$3.85

52-Week Range

A$1.02

Now: A$3.39▼

A$4.45

Volume10.19 million shs

Average Volume2.19 million shs

Market Capitalization$1.82 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Mesoblast.

2.1 Community Rank

Outperform Votes
Mesoblast has received 64 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Mesoblast has received 88 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Mesoblast has received 57.89% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote “Outperform” if you believe MSB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MSB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Mesoblast does not currently pay a dividend.
Dividend Growth
Mesoblast does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mesoblast insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Mesoblast are expected to grow in the coming year, from A($0.04) to A$0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mesoblast is -22.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mesoblast is -22.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Mesoblast has a PEG Ratio of 20.71. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Mesoblast has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.55 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ASX

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolASX:MSB

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.mesoblast.com

Phone+61-3-96396036

Debt

Debt-to-Equity Ratio18.83

Current Ratio1.21

Quick Ratio1.09

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E Growth20.71

Sales & Book Value

Annual Sales$22.47 million

Price / Sales80.99

Cash FlowA$0.15 per share

Price / Cash Flow22.30

Book ValueA$0.94 per share

Price / Book3.62

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees81

Outstanding Shares536,779,008

Market Cap$1.82 billion

Next Earnings DateN/A

OptionableOptionable

Receive MSB News and Ratings via Email

Sign-up to receive the latest news and ratings for MSB and its competitors with MarketBeat's FREE daily newsletter.

Mesoblast (ASX:MSB) Frequently Asked Questions

How has Mesoblast's stock been impacted by COVID-19 (Coronavirus)?

Mesoblast's stock was trading at A$1.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MSB stock has increased by 87.3% and is now trading at A$3.39. View which stocks have been most impacted by Coronavirus.

How were Mesoblast's earnings last quarter?

Mesoblast limited (ASX:MSB) released its earnings results on Thursday, February, 21st. The company reported ($0.09) earnings per share (EPS) for the quarter. View Mesoblast's earnings history.

Has Mesoblast been receiving favorable news coverage?

News articles about MSB stock have been trending negative on Monday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mesoblast earned a daily sentiment score of -2.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutMesoblast.

Who are some of Mesoblast's key competitors?

Some companies that are related to Mesoblast include MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR), MorphoSys (MOR), MorphoSys (MOR), Vir Biotechnology (VIR), BTG (BTG), Abcam (ABC), Cronos Group (CRON), Kodiak Sciences (KOD), Viela Bio (VIE), Genus (GNS), Polynovo (PNV), NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV) and BELLUS Health (BLU). View all competitors.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Mesoblast (MESO), Alliance Resource Partners (ARLP), OceanaGold (OGC), Bubs Australia (BUB), GENFIT S A/ADR (GNFT), Pluristem Therapeutics (PSTI), Starpharma (SPL), Viking Therapeutics (VKTX), Alkane Resources (ALK) and Alcidion Group (ALC).

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:

Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
Dr. Kenneth M. Borow M.D., Exec. (Age 71)

What is Mesoblast's stock symbol?

Mesoblast trades on the ASX under the ticker symbol "MSB."

What is Mesoblast's stock price today?

One share of MSB stock can currently be purchased for approximately A$3.39.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $1.82 billion and generates $22.47 million in revenue each year. Mesoblast employs 81 workers across the globe.

What is Mesoblast's official website?

The official website for Mesoblast is www.mesoblast.com.

How can I contact Mesoblast?

Mesoblast's mailing address is L 38 55 Collins St, MELBOURNE, VIC 3000, Australia. The company can be reached via phone at +61-3-96396036.

This page was last updated on 6/1/2020 by MarketBeat.com Staff